When the Grey Zone Gets a Name: The Cam Hanes–Sage Canaday Controversy

A banned peptide. A 10-minute PR at 58. An elite runner who went to USADA. And a sport asking itself uncomfortable questions about who the rules are actually for.

How It Started

On April 26, Cam Hanes — the 58-year-old bowhunter, podcaster, and social media figure with millions of followers — ran 2:39:11 at the Eugene Marathon, winning his age group and the masters division at what is also the Oregon USATF Marathon Championship.

On its own, that's a remarkable result for a 58-year-old. The problem was context. Hanes' performances had consistently hovered between 2:50 and 2:55 for years. A sudden improvement of more than 10 minutes was impossible to ignore.

What happened next turned a performance outlier into one of the most talked-about controversies in running this year.

The Instagram Comment That Changed Everything

In an Instagram comment exchange with elite runner Sage Canaday shortly after the race, Hanes acknowledged that he uses BPC-157 — a synthetic peptide marketed for tendon and tissue repair that has been on WADA's prohibited list since January 2022 under category S0: non-approved substances. It is banned at all times, in and out of competition. A first violation carries a default four-year ban.

Hanes didn't deny it. Rather, he doubled down. "I'm an old man," he said on his podcast. "If this stuff might work and save me from surgery, I'm going to try it. Why wouldn't I? I don't have USA on my jersey."

A post from 2011 on Hanes' own website also lists a testosterone stack. In his recent comments to Canaday, Hanes said he is no longer on TRT and that his current testosterone reading is around 500 ng/dL — inside the typical range for adult men. But a total reading alone does not establish WADA compliance.

Who Is Sage Canaday — and Why Does It Matter?

Canaday is one of the most credentialed mountain and ultra runners in North America. He ran for Cornell, qualified for the US Olympic Trials at 21 — the youngest-ever qualifier at that time — won the Ivy League 10,000m championship, has set six FKTs, and ran a 2:16:52 marathon in San Diego. He is not a social media personality picking a fight. He is a career competitive runner defending the integrity of the sport he has dedicated his life to.

Canaday filed a tip with the US Anti-Doping Agency and has been in direct contact with the agency. He provided screenshots, timestamps, and video recordings of the Instagram exchange to USADA — though the agency has not released any information publicly.

The Eugene Marathon also complied with a request from USADA for participant registration records.

What Is BPC-157 — and Why Are So Many Runners on It?

BPC-157 is a short chain of amino acids — a synthetic peptide derived from a protein found in human gastric juice. It's been widely marketed for tendon and tissue repair, and has become increasingly common in the middle-aged endurance community as an injury recovery tool.

BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans. The peptide has gained popularity among athletes and the general public for injury recovery, leading WADA to ban it in 2022. Health authorities discourage its use due to insufficient human safety data, and because the compound promotes blood vessel formation — angiogenesis — there are theoretical concerns about potential cancer promotion that require further investigation.

No therapeutic use exemption is available for it. USADA can hand out a four-year suspension for using it. CJC-1295, ipamorelin, TB-500, and most of the other peptides on the standard influencer stack are banned too.

The FDA Twist — a Story Within a Story

Here's where the controversy gets genuinely complicated. On April 15 — just 11 days before Hanes ran his 2:39 — the FDA announced it would imminently remove BPC-157 from its list of bulk drug substances that raise significant safety concerns, and signalled that its July 2026 meeting would explore giving these peptides full approval.

That doesn't change WADA's ban, which remains in effect. But it adds a layer of ambiguity to the regulatory picture that Hanes and his supporters have leaned into heavily. The FDA reconsidering the safety profile of BPC-157 is not the same as WADA delisting it — but in the court of public opinion, it complicates the narrative.

The Bigger Picture

At the time of writing, Hanes has not been charged with a rules violation. His Eugene result stands. His age-group win stands.

But the conversation the controversy has opened up is more important than any single result. Running — particularly trail and ultra running — has always existed in a grey zone when it comes to doping. The sport lacks the testing infrastructure of track and field. Age-group races aren't policed the way professional events are. And the community has a long-standing culture of celebrating grit and self-experimentation that sometimes blurs the line between pushing through injury and pharmaceutical assistance.

Cam Hanes is not a professional athlete competing for prize money or Olympic selection. He is a 58-year-old who runs because he loves it, with a social media platform and a sponsorship portfolio that gives him enormous influence over the middle-aged running community. That influence is precisely why Canaday acted — not to punish one man, but to draw a line that the sport keeps refusing to draw for itself.

The rules exist for a reason. They protect the runners who don't use banned substances — the ones lining up at Eugene, at Boston, at every age-group race across the country — from competing on an unequal playing field. "I don't have USA on my jersey" is a revealing statement. It suggests the rules only matter when they apply to elite competition. The runners who finished behind Hanes in the masters division at Eugene might disagree.

USADA is now involved. The sport is watching.